APA (7th ed.) Citation

A, A., J, C., B, P., MT, S., L, F., L, R., . . . DM, S. (2026). EDL6D, a bioactive peptide phenocopying SHBG-associated metabolic effects: A new preclinical lead compound for treating the metabolic dysfunction-associated fatty liver disease. Journal of translational medicine, 24(1), . https://doi.org/10.1186/s12967-026-08305-9

Chicago Style (17th ed.) Citation

A, Alvarez-Guaita, Cabrera-Serra J, Perez-Gonzalez B, Salcedo-Allende MT, Fuertes-Rioja L, Ramos-Perez L, Hernandez C, Simó R, and Selva DM. "EDL6D, a Bioactive Peptide Phenocopying SHBG-associated Metabolic Effects: A New Preclinical Lead Compound for Treating the Metabolic Dysfunction-associated Fatty Liver Disease." Journal of Translational Medicine 24, no. 1 (2026). https://doi.org/10.1186/s12967-026-08305-9.

MLA (9th ed.) Citation

A, Alvarez-Guaita, et al. "EDL6D, a Bioactive Peptide Phenocopying SHBG-associated Metabolic Effects: A New Preclinical Lead Compound for Treating the Metabolic Dysfunction-associated Fatty Liver Disease." Journal of Translational Medicine, vol. 24, no. 1, 2026, https://doi.org/10.1186/s12967-026-08305-9.